Some Chinese dairy producers have seen gross profit margins of their infant formula milk powder products continue to decline due to the impact of foreign brands, high costs and inventory pressures. So, more producers are trying to target healthy products. The two-child policy in China didn’t trigger sales growth of the domestic dairy sectors, which had their growth dampened by the boom in cross-border e-commerce, price competition and other factors…Full Article: ECNS.cn Jan 2017
- In December 2016, Biostime International Holdings acquired the remaining 17% share of Australia’s Swisse Wellness Group for AUD 311 million (US$224 million).
- From January to September 2016, Biostime International Holdings recorded a 3.3% year-on-year decline of its infant formula and health care sales to CNY 2.67 billion (~US400 million).
- In September 2015, Biostime International Holdings acquired an 83% stake in Australia’s Swisse Wellness Group (vitamin and nutritional supplements producer) for AUD 1.38 billion (US$989 million).
- Founded in 2001 and headquartered in Shenzhen, Guangdong Province, Green’s Shenzhen Leveking Bio-engineering is a food enzyme producer that focuses on supplying the animal feed, dairy, and bakery industries (among others). The company’s food and animal feed enzyme product line includes lipase, xylanase, mannosidase, phytase, and protease.
- Founded in 1999 and headquartered in Guangzhou, Guangdong Province, Biostime International Holdings (HKG:1112) is an infant formula and milk powder producer. The company initially focused on probiotic products.
Hong Kong Trends